How big is Harvard Bioscience, Inc.?

As of Jun 18, Harvard Bioscience, Inc. has a market capitalization of 21.69 million and reported net sales of 91.40 million, with a net profit loss of 58.05 million over the latest four quarters.

As of Jun 18, Harvard Bioscience, Inc. has a market capitalization of 21.69 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 91.40 million for the latest four quarters. However, it also experienced a net profit loss of 58.05 million during the same period.<BR><BR>As of Dec 24, the company's shareholder's funds amounted to 63.34 million, while total assets were reported at 126.64 million.

What does Harvard Bioscience, Inc. do?

Harvard Bioscience, Inc. develops and markets scientific instruments and lab consumables for research and testing in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $22 million and a net profit loss of $50 million, with a market cap of $21.69 million.

Overview: <BR>Harvard Bioscience, Inc. is a developer, manufacturer, and marketer of scientific instruments, systems, and lab consumables used for basic research, drug discovery, clinical, and environmental testing, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market classification.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 22 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -50 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 21.69 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 2.15 <BR>Return on Equity: -61.48% <BR>Price to Book: 1.46<BR><BR>Contact Details: <BR>Address: 84 OCTOBER HILL RD, HOLLISTON MA: 01746 <BR>Tel: 1 508 8938999 <BR>Website: https://www.harvardbioscience.com/

Should I buy, sell or hold Harvard Bioscience, Inc.?

Who are in the management team of Harvard Bioscience, Inc.?

As of March 2022, the management team of Harvard Bioscience, Inc. includes Mr. James Green as Chairman, President, and CEO, with Mr. Bertrand Loy serving as Lead Independent Director and several independent directors including Ms. Katherine Eade and Mr. Alan Edrick.

As of March 2022, the management team of Harvard Bioscience, Inc. includes Mr. James Green, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the Board of Directors features Mr. Bertrand Loy as the Lead Independent Director, along with independent directors Ms. Katherine Eade, Mr. Alan Edrick, Mr. John Kennedy, and Mr. Thomas Loewald.

Is Harvard Bioscience, Inc. technically bullish or bearish?

As of June 3, 2025, Harvard Bioscience, Inc. shows a mildly bearish trend with mixed technical indicators, including a mildly bullish weekly MACD and a bearish monthly MACD, alongside poor performance with a year-to-date return of -77.09%.

As of 3 June 2025, the technical trend for Harvard Bioscience, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The RSI is bullish on a monthly basis but shows no signal weekly. Moving averages indicate a mildly bearish trend on a daily basis. The stock has performed poorly over multiple periods, with a year-to-date return of -77.09% compared to the S&P 500's 12.22%, and a one-year return of -82.62% against the S&P 500's 17.14%.